SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.

“We are excited about the long-term growth opportunities for oral TPOXX and believe this amendment to the Meridian promotion agreement will be instrumental in driving our expansion efforts for TPOXX outside the U.S.,” said Diem Nguyen, Chief Executive Officer. “This strategic move, which gives SIGA greater control, will enable us to meet our global customers’ needs more effectively during these uncertain times of orthopox threats. The ability to forge direct relationships with key international stakeholders is essential to our plans to expand access to TPOXX and maximize value creation.”

This amendment, which extends the term of the promotion agreement by two years with respect to specific territories including the European Union, gives SIGA primary responsibility for promoting oral TPOXX. Certain existing contracts under the promotion agreement, including Meridian’s contract with the European Commission’s DG Health Emergency Preparedness and Response Authority (HERA), will remain in effect.

ABOUT SIGA TECHNOLOGIES, INC. 
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.

ABOUT TPOXX
TPOXX is a novel small-molecule drug and the U.S. maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.